NCT05544786View on ClinicalTrials.gov

Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants.

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 28, 2022

Primary Completion Date

November 29, 2022

Study Completion Date

November 29, 2022

Conditions
Biological Availability
Interventions
DRUG

Nirmatrelvir/ ritonavir

Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition

DRUG

Nirmatrelvir/Ritonavir

Single oral dose of nirmatrelvir/ritonavir mixed in water under fasted condition

DRUG

Nirmatrelvir/Ritonavir

Single oral dose of nirmatrelvir/ritonavir mixed in infant formula under fasted condition

DRUG

Nirmatrelvir/ritonavir

Single oral dose of nirmatrelvir/ritonavir mixed in vanilla pudding under fasted condition

DRUG

Nirmatrelvir/ritonavir

Single oral dose of nirmatrelvir/ritonavir mixed in vanilla pudding under fed condition

Trial Locations (1)

B-1070

Pfizer Clinical Research Unit - Brussels, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05544786 - Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants. | Biotech Hunter | Biotech Hunter